Insmed (INSM) reported a Q3 net loss Thursday of $1.27 per diluted share, wider than the loss of $1.11 a year earlier.
Analysts polled by Capital IQ expected a loss of $1.21.
Net product revenues for the quarter ended Sept. 30 were $93.4 million, up from $79.1 million a year earlier.
Analysts surveyed by Capital IQ expected $93.2 million.
The company said it continues to expect fiscal 2024 revenue for antibiotic drug Arikayce to be between $340 million and $360 million.
Shares of the company were down 7.3% in recent premarket activity.
Price: 65.16, Change: -5.13, Percent Change: -7.30
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。